Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Jun;133(6):642-5.
doi: 10.1111/j.1365-2141.2006.06094.x.

Overexpression of the VAV proto-oncogene product is associated with B-cell chronic lymphocytic leukaemia displaying loss on 13q

Rosario M Prieto-Sánchez  1 , José A Hernández, Juan L García, Norma C Gutiérrez, Jesús San Miguel, Xosé R Bustelo, Jesús M Hernández
Affiliations

Overexpression of the VAV proto-oncogene product is associated with B-cell chronic lymphocytic leukaemia displaying loss on 13q

Rosario M Prieto-Sánchez et al. Br J Haematol. 2006 Jun.

Abstract

The expression of the VAV proto-oncogene in 57 patients with chronic myeloproliferative disease (CMD), B-cell acute lymphoblastic leukaemia (B-ALL) and B-cell non-Hodgkin Lymphoma (B-NHL), and 61 with B-cell chronic lymphocytic leukaemia (B-CLL) was analysed. VAV overexpression was observed in 19.5% of cases and 81% of VAV-positive tumours also displayed VAV phosphorylation. Overexpression was not observed in B-ALL or CMD, but 13% of B-NHL and 34.4% of B-CLL patients (P = 0.002) overexpressed VAV. The overexpression and phosphorylation of VAV was detected more frequently in 13q- chronic lymphocytic leukaemias (71.4%) versus other B-CLLs (23.4%, P = 0.001). Overexpression of VAV protein is a frequent event in patients with B-CLL displaying loss of 13q sequences.

PubMed Disclaimer

Figures

Fig 1
Fig 1
(A) Analysis of VAV protein levels in bone marrow (BM) cells from B-cell chronic lymphocytic leukaemia (B-CLL) patients. Total cellular lysates obtained from BM cells from either B-CLL patients (lanes 1–4) or healthy individuals (lanes 5–7) were subjected to immunoblot analysis with anti-VAV antibodies (upper panel). After stripping, the same filter was subjected to immunoblot analysis with anti-phosphoVAV Y174 antibodies (lower panel). As a positive control, a total cellular extract from quiescent COS-1 cells ectopically expressing an epitope-tagged version of VAV that were stimulated with epidermal growth factor for 10 min at 37°C was included (lane 8). (B) Analysis of VAV protein expression levels in BM cells from B-CLL patients. Total cellular lysates, derived from BM cells from six independent B-CLL patients (lanes 1 to 6, top), were analysed as indicated in (A). The electrophoretic mobility of VAV and phosphorylated VAV proteins is indicated by arrows (left side of panels). The position of molecular weight markers is indicated on the right.
See this image and copyright information in PMC

References

    1. Bustelo XR. Regulatory and signalling properties of the Vav family. Molecular and Cellular Biology. 2000;20:1461–1477. - PMC - PubMed
    1. Caloca MJ, Zugaza JL, Matallanas D, Crespo P, Bustelo XR. Vav mediates Ras stimulation by direct activation of the GDP/GTP exchange factor Ras GRP1. EMBO Journal. 2003;22:3326–3336. - PMC - PubMed
    1. Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature. 2002;420:629–635. - PubMed
    1. Fernández-Zapico ME, González-Paz NC, Weiss E, Savoy DN, Molina JR, Fonseca R, Smyrk TC, Chari ST, Urrutia R, Billadeau DD. Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis. Cancer Cell. 2005;7:39–49. - PubMed
    1. Hernández JM, González MB, Granada I, Gutiérrez N, Chillón C, Ramos F, Ribera JM, González M, Feliu E, San Miguel JF. Detection of inv(16) and t(16;16) by fluorescence in situ hybridization in acute myeloid leukaemia M4Eo. Haematologica. 2000;85:481–485. - PubMed

Publication types

MeSH terms